Preview

Пульмонология

Расширенный поиск

Симбикорт (будесонид / формотерол): одновременное применение в качестве базисной терапии и для купирования симптомов бронхиальной астмы

https://doi.org/10.18093/0869-0189-2007-0-2-98-103

Полный текст:

Об авторах

А. Г. Чучалин
ФГУ НИИ пульмонологии Росздрава
Россия
г. Москва


А. Н. Цой
ММА им. И.М.Сеченова
Россия
г. Москва


В. В. Архипов
ММА им. И.М.Сеченова
Россия
г. Москва


Список литературы

1. Partridge M.R., van der Molen T., Myrseth S. E., Busse W.W. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm. Med. 2006; 6: 13.

2. Чучалин А.Г., Цой А.Н., Архипов В.В., Гавришина Е.А. Бронхиальная астма в России: результаты национального исследования качества медицинской помощи больным бронхиальной астмой. Пульмонология 2006; 2: 94–102.

3. Holt S., Suder A., Weatherall M. et al. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. Brit. Med. J. 2001; 323: 1–8.

4. Masoli M., Holt S., Weatherall M., Beasley R. Doseresponse relationship of inhaled budesonide in adult asthma: a meta-analysis. Eur. Respir. J. 2004; 23: 552–558.

5. Bateman E.D., Boushey H.A., Bousquet J. et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL Study. Am. J. Respir. Crit. Care Med. 2004; 170: 836–844.

6. Tattersfield A.E., Postma D.S., Barnes P.J. et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. Am. J. Respir. Crit. Care Med. 1999; 160: 594–599.

7. GINA Report, Global Strategy for Asthma Management and Prevention. Published November 2006. http://www.ginasthma.org/download.asp?intId=217

8. Pauwels R., Lofdahl C.G., Postma D.S. et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N. Engl. J. Med. 1997; 337 (20): 1405.

9. FitzGerald J.M., Becker A., Sears M.R. et al. Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations. Thorax 2004; 59: 550–556.

10. Harrison T.W., Oborne J., Newton S. et al. Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Lancet 2004; 363: 271–275.

11. Reddel H.K., Barnes D.J. Pharmacological strategies for self-management of asthma exacerbations. Eur. Respir. J. 2006; 28 (1): 182–199.

12. Fitzgerald M. et al. Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with traditional fixed dosing: A five-month multicentre Canadian study. Can. Respir. J. 2003; 10: 427–434.

13. Stallberg B., Olsson P., Jorgensen L.A., Lindarck N., Ekstrom T. Budesonide/formoterol adjustable maintenance dosing reduces asthma exacerbations versus fixed dosing. Int. J. Clin. Pract. 2003; 57 (8): 656–661.

14. Buhl R., Kardos P., Richter K. et al. The effect of adjustable dosing with budesonide/formoterol on health?related quality of life and asthma control compared with fixed dosing. Cur. Med. Res. Opin. 2004; 20 (8): 1209?1220.

15. Serrier P., Roche N., Pello J.Y., Larguier J.S., Mezzi K. Control of asthma by treatment with inhaled corticosteroids and prolonged action beta 2-agonists in free or fixed combination. Results of the ALISE study. Fr. Pres. Med. 2003; 32 (11): 493–497.

16. Aalbers R., Backer V., Kava T.T.K. et al. Adjustable maintenance dosing with budesonide/formoterol compared with fixed dose salmeterol/fluticasone in moderate to severe asthma. Cur. Med. Res. Opin. 2004; 20 (2): 225–240.

17. Gibson P.G. Teaching old drugs new tricks: asthma therapy adjusted by patient perception or noninvasive markers. Eur. Respir. J. 2005; 25: 397–399.

18. Ringdal N. et al. Respir. Med. 1998; 92: 1017–1021.

19. Busse W.W. et al. J. Allergy Clin. Immunol. 1998; 101: 457–463.

20. Vathenen A.S., Knox A.J., Wisniewski A., Tattersfield A.E. Time course of change in bronchial reactivity with an inhaled corticosteroid in asthma. Am. Rev. Respir. Dis. 1991; 143: 1317–1321.

21. Le Merre C., Bengtsson T., Carlholm M., Ostinelli J. Effect on lung function and inflammatory markers of single doses of inhaled budesonide in asthmatics. Am. J. Respir. Crit. Care Med. 1997; 155: A352.

22. Fitzgerald J.M., Shragge D., Haddon J. et al. A randomized, controlled trial of high dose, inhaled budesonide versus oral prednisone in patients discharged from the emergency department following an acute asthma exacerbation. Can. Respir. J. 2000; 7: 61–67.

23. Nana A., Youngchaiyud P., Charoenratanakul S. et al. Highdose inhaled budesonide may substitute for oral therapy after an acute asthma attack. J. Asthma 1998; 35: 647–655.

24. Pauwels R.A., Sears M.R., Campbell M. et al. Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial. Eur. Respir. J. 2003; 22: 787–794.

25. Ind P.W., Villasante C., Shiner R.J. et al. Safety of formoterol by Turbuhaler1 as reliever medication compared with terbutaline in moderate asthma. Eur. Respir. J. 2002; 20: 859–866.

26. Jonkers R.E., Bantje T.A., Aalbers R. Onset of relief of dyspnoea with budesonide/formoterol or salbutamol following methacholine-induced severe bronchoconstriction in adults with asthma: a double-blind, placebo-controlled study. Respir. Res. 2006; 7: 141.

27. Balanag V.M., Yunus F., Yang P.C., Jorup C. Efficacy and safety of budesonide/formoterol compared with salbutamol in the treatment of acute asthma. Pulm. Pharmacol. Ther. 2006; 19 (2): 139–147.

28. van der Woude H.J., Boorsma M., Bergqvist P.B. et al. Budesonide/formoterol in a single inhaler rapidly relieves methacholine-induced moderate-to-severe bronchoconstriction. Pulm. Pharmacol. Ther. 2004; 17 (2): 89–95.

29. Rabe K.F., Pizzichini E., Bjorn Stallberg B. et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma. Chest 2006; 129: 246–256.

30. Scicchitano R., Aalbers R., Ukena D. et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Cur. Med. Res. Opin. 2004;20 (9): 1403–1418.

31. O'Byrne P.M., Bisgaard H., Godard P.P. et al. Budesonide/ formoterol combination therapy as both maintenance and reliever medication in asthma. Am. J. Respir. Crit. Care Med. 2005; 171: 129–136.

32. Rabe K.F., Atienza T., Magyar P. et al. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 2006; 368 (9537): 744–753.

33. Vogelmeier C., D'Urzo A., Pauwels R. et al. Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur. Respir. J. 2005; 26 (5): 819–828.

34. Kuna P., Peters M.J., Buhl R. Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations versus a higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone. Abstract presented at the ERS Congress 2006.


Для цитирования:


Чучалин А.Г., Цой А.Н., Архипов В.В. Симбикорт (будесонид / формотерол): одновременное применение в качестве базисной терапии и для купирования симптомов бронхиальной астмы. Пульмонология. 2007;(2):98-103. https://doi.org/10.18093/0869-0189-2007-0-2-98-103

For citation:


Chuchalin A.G., Tsoy A.N., Arkhipov V.V. Symbicort (budesonide / formoterol) as a single inhaler for maintenance and reliever therapy of asthma. PULMONOLOGIYA. 2007;(2):98-103. (In Russ.) https://doi.org/10.18093/0869-0189-2007-0-2-98-103

Просмотров: 51


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)